Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Indira Brar

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Journal of Infection and Public Health|June 11, 2023
Outcomes associated with SARS-CoV-2 reinfection in individuals with natural and hybrid immunityGeehan Suleyman, Raef Fadel, Kunj Patel, et al.
Open Forum Infectious Diseases|July 13, 2022
Progression to Critical Illness and Death in Patients With Breakthrough HospitalizationsGeehan Suleyman, Raef Fadel, Ayman Alsaadi, et al.
Open Forum Infectious Diseases|April 19, 2022
Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough InfectionsGeehan Suleyman, Raef Fadel, Indira Brar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 18, 2020
The Impact of Sociodemographic Factors, Comorbidities, and Physiologic Responses on 30-Day Mortality in Coronavirus Disease 2019 (COVID-19) Patients in Metropolitan DetroitJoseph Miller, Raef A Fadel, Amy Tang, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 6, 2020
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19Samia Arshad, Paul Kilgore, Zohra S Chaudhry, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|August 4, 2020
A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19Marcus Zervos, Samia Arshad, Paul Kilgore, et al.
The Lancet. HIV|June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialJean-Michel Molina, Douglas Ward, Indira Brar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2021
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label StudyDebbie Hagins, Princy Kumar, Michael Saag, et al.
Lancet (London, England)|September 5, 2017
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialJoel Gallant, Adriano Lazzarin, Anthony Mills, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 23, 2025
Risk of severe bacterial infections including TB before and after immediate or deferred antiretroviral therapy: A multicenter, prospective, cohort studyTomas O Jensen, Shweta Sharma, Anchalee Avihingsanon, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Journal of Infection and Public Health|June 11, 2023
Outcomes associated with SARS-CoV-2 reinfection in individuals with natural and hybrid immunityGeehan Suleyman, Raef Fadel, Kunj Patel, et al.
Open Forum Infectious Diseases|July 13, 2022
Progression to Critical Illness and Death in Patients With Breakthrough HospitalizationsGeehan Suleyman, Raef Fadel, Ayman Alsaadi, et al.
Open Forum Infectious Diseases|April 19, 2022
Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough InfectionsGeehan Suleyman, Raef Fadel, Indira Brar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 18, 2020
The Impact of Sociodemographic Factors, Comorbidities, and Physiologic Responses on 30-Day Mortality in Coronavirus Disease 2019 (COVID-19) Patients in Metropolitan DetroitJoseph Miller, Raef A Fadel, Amy Tang, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 6, 2020
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19Samia Arshad, Paul Kilgore, Zohra S Chaudhry, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|August 4, 2020
A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19Marcus Zervos, Samia Arshad, Paul Kilgore, et al.
The Lancet. HIV|June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialJean-Michel Molina, Douglas Ward, Indira Brar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2021
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label StudyDebbie Hagins, Princy Kumar, Michael Saag, et al.
Lancet (London, England)|September 5, 2017
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialJoel Gallant, Adriano Lazzarin, Anthony Mills, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 23, 2025
Risk of severe bacterial infections including TB before and after immediate or deferred antiretroviral therapy: A multicenter, prospective, cohort studyTomas O Jensen, Shweta Sharma, Anchalee Avihingsanon, et al.
Pageof 5